Pfizer Inc. 2022 Form 10-K Summary
Business context and reporting period
Pfizer is a global biopharmaceutical company focused on discovering, developing, manufacturing and commercializing medicines and vaccines. This filing covers the fiscal year ended December 31, 2022; it is an annual report, not a standalone fourth-quarter report. Pfizer reported one reportable segment, Biopharma, and a separate contract development and manufacturing business, Pfizer CentreOne (PC1).
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $100.3 billion | $81.3 billion |
| Income from continuing operations | $31.4 billion | $22.5 billion |
| Net income attributable to Pfizer shareholders | $31.4 billion | $22.0 billion |
| Diluted EPS, GAAP | $5.47 | $3.85 |
| Adjusted diluted EPS, non-GAAP | $6.58 | $4.06 |
| Cash from continuing operating activities | $29.3 billion | $32.9 billion |
| Capital expenditures | $3.2 billion | $2.7 billion |
- Revenue rose 23% reported (30% operationally), with a $5.5 billion unfavorable foreign-exchange impact. Comirnaty and Paxlovid were the primary growth drivers.
- Cost of sales was $34.3 billion, or 34.2% of revenue, compared with 37.9% in 2021. R&D expense was $11.4 billion; selling, informational and administrative expense was $13.7 billion.
- At year-end, cash and cash equivalents were $0.4 billion and short-term investments were $22.3 billion. Current assets totaled $51.3 billion and current liabilities $42.1 billion.
- Long-term debt carrying value was $32.9 billion, with $2.9 billion in short-term borrowings including current long-term debt. Pfizer had access to a $7 billion revolving credit facility, substantially unused. Moody’s upgraded its long-term debt rating to A1; Moody’s and S&P outlooks were stable.
- Pfizer paid $9.0 billion in dividends and repurchased $2.0 billion of common stock. The board declared a quarterly dividend of $0.41 per share for the first quarter of 2023.
Material changes versus the prior comparable period
- Revenue increased $19.0 billion, driven chiefly by Paxlovid revenue of $18.9 billion (versus $76 million in 2021) and Comirnaty revenue of $37.8 billion (up 10% operationally). Excluding these COVID-19 products, revenue grew 2% operationally.
- Growth outside COVID-19 products included the Prevnar family, Eliquis and the Vyndaqel family. Declines included Xeljanz, Ibrance, Chantix/Champix and Sutent; Sutent faced loss of exclusivity.
- Operating cash flow declined 11% to $29.3 billion, primarily reflecting higher payments to BioNTech for Comirnaty profit sharing and an increase in noncurrent inventories, partly offset by higher income adjusted for noncash items.
- Pfizer spent $23.0 billion, net of cash acquired, on the Biohaven, Arena and Global Blood Therapeutics acquisitions. Identifiable intangible assets increased to $43.4 billion from $25.1 billion.
- Reported net income and cash flow comparisons include significant non-operating and other period-specific items. In particular, 2021 included net gains on equity securities and substantial pension benefit credits; 2022 included net equity-security losses and restructuring and acquisition costs.
Outlook, commentary, risks and unusual items
- As of January 31, 2023, management forecast 2023 revenue of $67 billion to $71 billion, an operational decline of about 31% at the midpoint from 2022. The expected decline was primarily due to lower Comirnaty and Paxlovid sales, partly offset by growth in the non-COVID portfolio, launches and acquired products.
- 2023 product forecasts were approximately $13.5 billion for Comirnaty and $8 billion for Paxlovid. Pfizer expected U.S. sales of both products to begin transitioning to commercial channels in the second half of 2023. Forecasts depend on demand, virus conditions, market share, contract deliveries and timing of the commercial transition.
- Management described COVID-19 product revenues as expected to reach a low point in 2023, with potential growth in 2024. Demand and the extent to which it is met by existing government-held supply remain uncertain.
- COVID-19 product inventory write-offs and related charges included $1.3 billion for inventory that had exceeded or was expected to exceed approved shelf lives and approximately $430 million for excess Paxlovid raw materials. Management also reported $1.1 billion of Paxlovid inventory write-offs and other charges and $600 million of Comirnaty inventory write-offs and other charges in its cost-of-sales discussion.
- Key risks include concentration in major products—Comirnaty and Paxlovid represented 57% of 2022 revenue, while ten products represented 82%—and expected patent expirations, generic and biosimilar competition, pricing and reimbursement pressure, clinical and regulatory uncertainty, manufacturing and supply risks, foreign-exchange exposure, and legal proceedings.
- The Inflation Reduction Act introduces Medicare drug-price negotiations beginning in 2026 and inflation-related rebates, among other provisions; Pfizer said the full business impact remained uncertain. Litigation and investigations include patent disputes involving Comirnaty and Paxlovid and product-related matters. Pfizer stated it did not believe pending matters would materially affect financial position, but could not estimate reasonably possible losses beyond accrued amounts.
- Pfizer reported $1.4 billion of restructuring charges and certain acquisition-related costs in 2022. Its transformation program included expected net savings of $2.3 billion from R&D optimization, primarily during 2023–2025; management also expected approximately $500 million of costs for that effort, primarily through 2023.
Most important facts for investors to verify
- Whether COVID-19 demand, government supply drawdowns and the commercial-channel transition support the 2023 revenue assumptions and a recovery in 2024.
- How acquired assets and pipeline programs perform, and whether restructuring costs and projected savings occur as planned.
- The timing and financial impact of patent expirations, generic competition and ongoing patent litigation, particularly for major revenue products.
- The eventual impact of the Inflation Reduction Act and other U.S. and international pricing and reimbursement measures.
- Inventory levels, further write-offs, operating cash flow and the balance between acquisition spending, debt, dividends and investment needs.
- Pfizer’s financial statements received an unqualified audit opinion, and the auditor reported effective internal control over financial reporting as of December 31, 2022.